How Much Upside is Left in Verve Therapeutics (VERV)? Wall Street Analysts Think 93.5%Zacks Investment Research • 07/25/23
Verve Establishes Global Collaboration with Lilly to Advance Verve's In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular DiseaseGlobeNewsWire • 06/15/23
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare ConferenceGlobeNewsWire • 06/01/23
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines DayGlobeNewsWire • 05/23/23
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/15/23
Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare ConferenceGlobeNewsWire • 05/09/23
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase GlobalBenzinga • 04/06/23
Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease DayGlobeNewsWire • 03/27/23
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human PrimatesGlobeNewsWire • 03/03/23
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/02/23
Verve Therapeutics: Opportunity For Quick Profit On Eventual Lifting Of Clinical HoldSeeking Alpha • 03/01/23
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial HypercholesterolemiaGlobeNewsWire • 02/14/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verve Therapeutics, Inc. - VERVNewsfile Corp • 01/07/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERVPRNewsWire • 01/04/23
Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing ConcernsInvestors Business Daily • 12/05/22